{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Progression-free survival events are death or first recurrence of progressive disease by International Myeloma Working Group Criteria.","groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"OG000","title":"IV Busulfan"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.","reportingStatus":"POSTED","timeFrame":"6 Months","title":"Percentage of Participants With Progression-free Survival Events","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}